

Care Step Pathway – Neuropathy (motor or sensory nerve impairment or damage)

Assessment

Look:

- Does the patient appear weak?
- Does the patient appear uncomfortable?
- Altered ambulation or general movement?
- If muscular weakness is present, any respiratory difficulties apparent?

Listen:

- Does the patient report weakness (unilateral or bilateral)?
- Does the patient report new or worsened pain, numbness, or tingling?
- Does the patient report difficulty walking or holding items?
- Does the patient describe walking on a cotton wool floor?

Recognize:

- Motor deficits
- Sensory deficits
- Mental status changes
- Paresthesias
- Laboratory values
- Past history of toxicities with other therapies
- Does the patient have diabetes mellitus?
- Are there neurologic signs and symptoms?
- Results of prior imaging
 - o Metastases to spinal cord
 - o Other metastases that may cause symptoms

Grading Toxicity: ULN

Grade 1 (Mild)

Peripheral Motor:

- Asymptomatic; clinical or diagnostic observations only
- No intervention indicated

Peripheral Sensory:

- Asymptomatic; loss of deep tendon reflexes or paresthesia

Grade 2 (Moderate)

Peripheral Motor:

- Moderate symptoms; limiting instrumental ADLs

Peripheral Sensory:

- Moderate symptoms; limiting instrumental ADLs

Grade 3 (Severe)

Peripheral Motor:

- Severe symptoms; limiting self-care ADLs; requires assistive devices

Peripheral Sensory:

- Severe symptoms; limiting self-care ADLs

Grade 4 (Potentially Life-Threatening)

Peripheral Motor:

- Life-threatening; urgent intervention indicated

Peripheral Sensory:

- Life-threatening; urgent intervention indicated

Grade 5 (Death)

Management

Overall Strategy:

- Screen for neuropathy causes: diabetes with HbA1C, vit B12, folate, TSH, and HIV, immunoglobulins IgG, IgA, IgM
- Rule out infectious, noninfectious, disease-related etiologies (medications, metabolic/endocrine disorders, environmental exposures, vascular or autoimmune, trauma)
- High-dose steroids* (0.5–1 mg/kg/day prednisone or equivalent) to be used
- Ipilimumab to be withheld for Grade 2 event, nivolumab for first occurrence of Grade 3 event, and pembrolizumab based on disease severity; ipilimumab to be discontinued for Grade 2 events persisting ≥ 6 weeks or inability to reduce steroid* dosage to ≤ 7.5 mg prednisone or equivalent per day; pembrolizumab or nivolumab to be discontinued for Grade 3/4 events that recur, persist ≥ 12 weeks, or inability to reduce steroid dosage to ≤ 10 mg prednisone or equivalent per day
- Guillain–Barré syndrome to be managed in the ICU setting, with particular attention to protection of the airway
- Neurology consult
 - o Consideration of electromyography and nerve conduction tests
 - o Immune globulin infusions
 - o Plasmapheresis
- Taper steroids* slowly over at least 4 weeks once symptoms improve
- If needed, obtain physical therapy or occupational therapy consult (for both functional assessment and evaluate safety of patient at home)
- Supportive medications for symptom management (e.g., gabapentin, pregabalin, or duloxetine)

Implementation:

- Compare baseline assessment; grade & document neuropathy and etiology (diabetic, medication, vascular, chemotherapy)
- Early identification and evaluation of patient symptoms
- Early intervention with lab work and office visit if neuropathy symptoms suspected

*Administering Corticosteroids:

Steroid taper instructions/calendar as a guide but not an absolute

- Taper should consider patient's current symptom profile
- Close follow-up in person or by phone, based on individual need & symptomatology
- Steroids cause indigestion; provide antacid therapy daily as gastric ulcer prevention while on steroids (e.g., proton pump inhibitor or H2 blocker if prednisone dosage is >20 mg/day)
- Review steroid medication side effects: mood changes (angry, reactive, hyperaware, euphoric, manic), increased appetite, interrupted sleep, oral thrush, fluid retention
- Be alert to recurring symptoms as steroids taper down & report them (taper may need to be adjusted)

Long-term high-dose steroids:

- Consider antimicrobial prophylaxis (sulfamethoxazole/trimethoprim double dose M/W/F; single dose if used daily) or alternative if sulfa-allergic (e.g., atovaquone [Mepron®] 1500 mg po daily)
- Consider additional antiviral and antifungal coverage
- Avoid alcohol/acetaminophen or other hepatotoxins
- If extended steroid use, risk for osteoporosis; initiate calcium and vitamin D supplements

RED FLAGS:

- **Guillain–Barré syndrome**
- **Myasthenia gravis**
- **Pain, numbness, and asymmetrical weakness consistent with a vasculitis syndrome**



ADLs = activities of daily living; HIV = human immunodeficiency virus; po = by mouth; TSH = thyroid-stimulating hormone